Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Sep
09
Today In Oncology
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo